Paul G Chaney is a notable inventor based in Mount Arlington, NJ (US). He has made significant contributions to the field of ocular drug delivery, holding a total of six patents. His work focuses on developing formulations that enhance the treatment of ocular conditions, particularly those involving neovascularization.

Latest Patents

Among his latest patents, Chaney has developed ocular formulations for drug delivery to the posterior segment of the eye. This invention relates to topical formulations that include a specific compound designed to treat ocular neovascularization. The compound is present in a solution or suspension ranging from about 0.005% to about 5.0% w/v, effectively delivering the compound to inhibit VEGF in the retina and/or choroid. Additionally, he has created formulations for drug delivery and protection of the anterior segment of the eye. This application involves topical formulations that comprise the same compound or its free base, along with a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, aimed at treating ocular neovascularization.

Career Highlights

Throughout his career, Chaney has worked with various companies, including Panoptica, Inc. His innovative work has positioned him as a key figure in the development of ocular therapies.

Collaborations

Chaney has collaborated with notable individuals in his field, including David P Bingaman and Martin B Wax. These partnerships have contributed to the advancement of his research and inventions.

Conclusion

Paul G Chaney's contributions to ocular drug delivery through his innovative patents highlight his expertise and dedication to improving treatment options for ocular conditions. His work continues to influence the field and pave the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.